INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)

Phase 1 & 2

Waitlist Available

Research Sponsored by Inovio Pharmaceuticals

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up screening up to week 52 (up to approximately 1 year)

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing INO-3107, a treatment designed to create a strong immune response against specific proteins of HPV6. It aims to help people with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and/or HPV-11, including both children and adults.

Eligible Conditions

Recurrent Respiratory Papillomatosis (RRP)

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ screening up to week 52 (up to approximately 1 year)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~screening up to week 52 (up to approximately 1 year)

This trial's timeline: 3 weeks for screening, Varies for treatment, and screening up to week 52 (up to approximately 1 year) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Secondary study objectives

Change in RRP Staging Assessment Scores Over Time

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: INO-3107Experimental Treatment2 Interventions

Participants will be administered one INO-3107 intramuscular (IM) injection followed by electroporation (EP) using CELLECTRA™ 2000 at Day 0, Week 3, Week 6, and Week 9.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

INO-3107

2020

Completed Phase 2

~40

CELLECTRA™ 2000

2020

Completed Phase 2

~480